CureVac GmbHProduct Pipeline Review - 2015
Summary
Global Markets Directs, CureVac GmbHProduct Pipeline Review - 2015, provides an overview of the CureVac GmbHs pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of CureVac GmbHs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides brief overview of CureVac GmbH including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of CureVac GmbHs human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement
Latest news and deals relating to the CureVac GmbHs pipeline products
Reasons to buy
Evaluate CureVac GmbHs strategic position with total access to detailed information on its product pipeline
Assess the growth potential of CureVac GmbH in its therapy areas of focus
Identify new drug targets and therapeutic classes in the CureVac GmbHs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of CureVac GmbH and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of CureVac GmbH
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Explore the dormant and discontinued projects of CureVac GmbH and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues
Table of Contents
List of Tables 5
List of Figures 5
CureVac GmbH Snapshot 6
CureVac GmbH Overview 6
Key Information 6
Key Facts 6
CureVac GmbH - Research and Development Overview 7
Key Therapeutic Areas 7
CureVac GmbH - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
CureVac GmbH - Pipeline Products Glance 16
CureVac GmbH - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
CureVac GmbH - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
CureVac GmbH - Drug Profiles 20
CV-9103 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CV-9104 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CV-9201 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CV-7201 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CV-8102 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Oligonucleotide for Cancer 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Oligonucleotide for Infectious Disease 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Oligonucleotide for Influenza Virus Infection 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
respiratory syncytial virus vaccine 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
HIV vaccine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Oligonucleotide for Rotavirus Infection 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Oligonucleotide for Undisclosed Indication 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Oligonucleotides for Undisclosed Indication 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
tuberculosis vaccine 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Vaccine for Oncology 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CureVac GmbH - Pipeline Analysis 36
CureVac GmbH - Pipeline Products by Target 36
CureVac GmbH - Pipeline Products by Route of Administration 37
CureVac GmbH - Pipeline Products by Molecule Type 38
CureVac GmbH - Recent Pipeline Updates 39
CureVac GmbH - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44
List of Tables
CureVac GmbH, Key Information 6
CureVac GmbH, Key Facts 6
CureVac GmbH - Pipeline by Indication, 2015 9
CureVac GmbH - Pipeline by Stage of Development, 2015 10
CureVac GmbH - Monotherapy Products in Pipeline, 2015 11
CureVac GmbH - Partnered Products in Pipeline, 2015 12
CureVac GmbH - Partnered Products/ Combination Treatment Modalities, 2015 13
CureVac GmbH - Out-Licensed Products in Pipeline, 2015 14
CureVac GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2015 15
CureVac GmbH - Phase II, 2015 16
CureVac GmbH - Phase I, 2015 17
CureVac GmbH - Preclinical, 2015 18
CureVac GmbH - Discovery, 2015 19
CureVac GmbH - Pipeline by Target, 2015 36
CureVac GmbH - Pipeline by Route of Administration, 2015 37
CureVac GmbH - Pipeline by Molecule Type, 2015 38
CureVac GmbH - Recent Pipeline Updates, 2015 39
CureVac GmbH, Other Locations 42
List of Figures
CureVac GmbH - Pipeline by Top 10 Indication, 2015 8
CureVac GmbH - Pipeline by Stage of Development, 2015 10
CureVac GmbH - Monotherapy Products in Pipeline, 2015 11
CureVac GmbH - Out-Licensed Products in Pipeline, 2015 14
CureVac GmbH - Pipeline by Top 10 Target, 2015 36
CureVac GmbH - Pipeline by Top 10 Route of Administration, 2015 37
CureVac GmbH - Pipeline by Top 10 Molecule Type, 2015 38
